Abstract
PurposeWe assessed the treatment outcome and the benefits of routine follow-up visits in T1 glottic laryngeal squamous cell carcinoma (LSCC).MethodsMedical records of patients diagnosed with stage T1 glottic LSCC (N = 303) in five Finnish university hospitals between 2003 and 2015 were reviewed. Moreover, data from the Finnish Cancer Registry and the Population Register Center were collected.ResultsOf all 38 recurrences, 26 (68%) were detected during a routine follow-up visit, and over half (21 of 38, 55%) presented without new symptoms. Primary treatment method (surgery vs. radiotherapy) was not connected with 5-year disease-specific survival (DSS) or laryngeal preservation rate.ConclusionThe majority of recurrences were detected on a routine follow-up visit, and local recurrences often presented without new symptoms. Routine post-treatment follow-up of T1 glottic LSCC seems beneficial.Trial registrationTrial registration number and date of registration HUS/356/2017 11.12.2017.
Highlights
T1 glottic laryngeal squamous cell carcinoma (LSCC) can be treated either with trans-oral laser surgery or with radiotherapy
Part of this study was presented at 26th Meeting of the Scandinavian Society for Head and Neck Oncology (SSHNO) 23–25 May 2018; Kuopio, Finland
The number of patients diagnosed per university hospital varied according to their population coverage
Summary
T1 glottic laryngeal squamous cell carcinoma (LSCC) can be treated either with trans-oral laser surgery or with radiotherapy. In Finland, LSCC is mainly treated in university hospitals. Part of this study was presented at 26th Meeting of the Scandinavian Society for Head and Neck Oncology (SSHNO) 23–25 May 2018; Kuopio, Finland. Working Group gives treatment guidelines for head and neck malignancies, and Multidisciplinary Tumor Board in each university hospital gives treatment recommendations for individual patients. Routine follow-up visits for head and neck cancer patients have been scheduled every 3–6 months during the 1st and 2nd year after treatment, and every 6–12 months thereafter, up to 5 years. The follow-up protocol varies between university hospitals, and clinicians may intensify or de-intensify follow-up intervals for individual patients, according to their risk profile
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
